Comprehensive Stock Comparison
Compare Evogene Ltd. (EVGN) vs Seres Therapeutics, Inc. (MCRB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs EVGN's 50.9% |
| Quality / Margins | MCRB | 15.4% net margin vs EVGN's -52.3% |
| Stability / Safety |  EVGN | Beta 0.54 vs MCRB's 1.21, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MCRB | -40.3% vs EVGN's -40.6% |
| Efficiency (ROA) | MCRB | 3.8% ROA vs EVGN's -10.5%, ROIC -180.9% vs -102.4% |
Who Each Stock Is For
Income & stability
EVGNbeta 0.54
Growth exposure
MCRBRev growth 448.4%, EPS growth -6.2%
Long-term compounding (10Y)
MCRB-98.5% 10Y total return vs EVGN's -98.8%
Sleep-well-at-night portfolio
EVGNLower volatility, beta 0.54, Low D/E 86.8%, current ratio 1.15x
Defensive / Recession hedge
EVGNBeta 0.54, current ratio 1.15x
Business Model
What each company does and how it makes money
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EVGN 3MCRB 0EVGN4/5 metricsEVGN6/8 metricsEVGN2/2 metricsEVGN leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
EVGN is the larger business by revenue, generating $5M annually — 15.0x MCRB's $351,000. MCRB is the more profitable business, keeping 15.4% of every revenue dollar as net income compared to EVGN's -52.3%.
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $351,000 |
| EBITDAEarnings before interest/tax | -$13M | -$99M |
| Net IncomeAfter-tax profit | -$3M | $5M |
| Free Cash FlowCash after capex | -$17M | -$23M |
| Gross MarginGross profit ÷ Revenue | +16.1% | -50.1% |
| Operating MarginEBIT ÷ Revenue | -2.8% | -294.7% |
| Net MarginNet income ÷ Revenue | -52.3% | +15.4% |
| FCF MarginFCF ÷ Revenue | -3.2% | -66.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +133.6% | +112.3% |
Valuation Metrics
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| Market CapShares × price | $7M | $80M |
| Enterprise ValueMkt cap + debt − cash | $5M | $141M |
| Trailing P/EPrice ÷ TTM EPS | -0.29x | -0.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.86x | — |
| Price / BookPrice ÷ Book value/share | 0.32x | 5.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MCRB delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-16 for EVGN. EVGN carries lower financial leverage with a 0.87x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCRB's 6.65x. On the Piotroski fundamental quality scale (0–9), EVGN scores 3/9 vs MCRB's 2/9, reflecting mixed financial health.
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -15.9% | +12.3% |
| ROA (TTM)Return on assets | -10.5% | +3.8% |
| ROICReturn on invested capital | -102.4% | -180.9% |
| ROCEReturn on capital employed | -66.5% | -67.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.87x | 6.65x |
| Net DebtTotal debt minus cash | -$2M | $61M |
| Cash & Equiv.Liquid assets | $15M | $31M |
| Total DebtShort + long-term debt | $13M | $92M |
| Interest CoverageEBIT ÷ Interest expense | -4.42x | — |
Total Returns (with DRIP)
A $10,000 investment in MCRB five years ago would be worth $240 today (with dividends reinvested), compared to $183 for EVGN. Over the past 12 months, MCRB leads with a -40.3% total return vs EVGN's -40.6%. The 3-year compound annual growth rate (CAGR) favors EVGN at -51.8% vs MCRB's -56.4% — a key indicator of consistent wealth creation.
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -25.8% | -39.7% |
| 1-Year ReturnPast 12 months | -40.6% | -40.3% |
| 3-Year ReturnCumulative with dividends | -88.8% | -91.7% |
| 5-Year ReturnCumulative with dividends | -98.2% | -97.6% |
| 10-Year ReturnCumulative with dividends | -98.8% | -98.5% |
| CAGR (3Y)Annualised 3-year return | -51.8% | -56.4% |
Risk & Volatility
EVGN is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than MCRB's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EVGN currently trades 34.6% from its 52-week high vs MCRB's 30.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 1.21x |
| 52-Week HighHighest price in past year | $2.42 | $29.98 |
| 52-Week LowLowest price in past year | $0.81 | $6.53 |
| % of 52W HighCurrent price vs 52-week peak | +34.6% | +30.5% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 32.0 |
| Avg Volume (50D)Average daily shares traded | 547K | 70K |
Analyst Outlook
| Metric | EVGNEvogene Ltd. | MCRBSeres Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1.25 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | 100 | 7.14 | -92.9% |
| Seres Therapeutics,… (MCRB) | 100 | 12.66 | -87.3% |
Seres Therapeutics,… (MCRB) returned -98% over 5 years vs Evogene Ltd. (EVGN)'s -98%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | $11M | $9M | -23.5% |
| Seres Therapeutics,… (MCRB) | $0.00 | $0.00 | — |
Evogene Ltd.'s revenue grew from $11M (2015) to $9M (2024) — a -2.9% CAGR. Seres Therapeutics, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
Evogene Ltd.'s net margin went from -155% (2015) to -194% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -0.68 | -2.89 | -325.0% |
| Seres Therapeutics,… (MCRB) | -46.6 | -18.86 | +59.5% |
Evogene Ltd.'s EPS grew from $-0.68 (2015) to $-2.89 (2024). Seres Therapeutics, Inc.'s EPS grew from $-46.60 (2015) to $-18.86 (2024).
Chart 5Free Cash Flow — 5 Years
Evogene Ltd. generated $-20M FCF in 2024 (+20% vs 2021). Seres Therapeutics, Inc. generated $-149M FCF in 2024 (-5077% vs 2021).
EVGN vs MCRB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is EVGN or MCRB a better buy right now?
Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EVGN or MCRB?
Over the past 5 years, Seres Therapeutics, Inc. (MCRB) delivered a total return of -97.6%, compared to -98.2% for Evogene Ltd. (EVGN). A $10,000 investment in MCRB five years ago would be worth approximately $240 today (assuming dividends reinvested). Over 10 years, the gap is even starker: MCRB returned -98.5% versus EVGN's -98.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EVGN or MCRB?
By beta (market sensitivity over 5 years), Evogene Ltd. (EVGN) is the lower-risk stock at 0.54β versus Seres Therapeutics, Inc.'s 1.21β — meaning MCRB is approximately 123% more volatile than EVGN relative to the S&P 500. On balance sheet safety, Evogene Ltd. (EVGN) carries a lower debt/equity ratio of 87% versus 7% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — EVGN or MCRB?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus -193.7% for Evogene Ltd. — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EVGN leads at -255.4% versus -294.7% for MCRB. At the gross margin level — before operating expenses — EVGN leads at 39.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — EVGN or MCRB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is EVGN or MCRB better for a retirement portfolio?
For long-horizon retirement investors, Evogene Ltd. (EVGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.54)). Both have compounded well over 10 years (EVGN: -98.8%, MCRB: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between EVGN and MCRB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.